Ireland
--:--IST
Recruiting Observational

Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy

NCT06353620 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2024-02-13
Last updated
2024-04-09

Condition(s) studied

EpilepsyAngelman SyndromeDup15q Syndrome

Investigational drug(s) / intervention(s)

High Density EEG recordingRey Complex Figure Test

High Density EEG recording: Recording of resting state high density EEG (128 channels)

Rey Complex Figure Test: Memeory functioning evaluation

Study summary

Recent studies have shown that the aperiodic part of the signal (neuronal avalanches) of electroencephalography (EEG) contains important information about the dynamics of neuronal networks. Indeed, this has helped to identify functionally altered areas in patients with temporal epilepsy by simply using the resting EEG signal. Furthermore, it has been seen that the propagation of neuronal avalanches (VNs) correlates with the morphological organization of the cerebral cortex. Therefore, NAs represent a measure with direct utility for studying functional reorganization pre and post drug/surgical treatment. In addition, the aperiodic portion of the signal may represent a noninvasive measure of the excitation/inhibition relationship, which is known of being altered both in epilepsy and in some rare neurodevelopmental syndromes (example: Angelman and Dup15q)

Eligibility

Sex
ALL
Min age
6 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * a diagnosis of focal or generalized epilepsy, Angelman syndrome, or Dup15q, confirmed by specialist evaluation; * at least one MRI scan of the brain that includes 3D T1 sequences; * at least one 128-channel HD-EEG recording; and * age between 6 and 75 years at the time of the evaluation of the present study; * ability to take part in a neuropsychological evaluation. Exclusion Criteria: * vascular causes or non-low-grade tumors as causes of epilepsy; * age different from the range 6-75 years; * neuroradiological examination not complete (absence T1 3D); * absence of HD-EEG 128-channel recording * inability to take part in a neuropsychological evaluation.

Primary outcome measure(s)

  • Differences in the network coherence values in theta and alpha band after treatment — 2 years
    The outcome 1 one will be finalized to measures the changes of the coherence values before and after the treatment. Coherence is a measure defining the strength of functional connectivity between two brain regions. The pre- and post-treatment changes will be investigated specifically in the theta and alpha EEG frequency band, since these two bands are the most affected in epilepsy condition.
  • Stability of the alpha frequency band in the EEG activity — 2 years
    The detrend fluctuation analysis (DFA) in the alpha band of the EEG power spectrum provides information on excitatory and inihibitory balance of neural activity. For the outcome 2, the exponent of the DFA in the alpha band will be compared between patients with rare neurodevelopmental disorders (Angelman and Dup15q) vs. the healthy control group.
  • Correlation of neural excitation and memory performance — 2 years
    Correlation between the aperiodic component of the EEG power specturum with the memory functioning obtained with the Rey Complex Figure Test, pre and post treatment

Trial sites (1)

FacilityCityRegionStatus
IRCCS E.Medea Conegliano Treviso Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06353620 on ClinicalTrials.gov ↗ ← All trials in Italy